Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 66

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 66
---
 Audit fees72 113 237 286 Consulting145 234 461 573 Insurance185 157 501 718 Other (e)134 181 347 523 Stock-based compensation289 296 944 1,259 General and administrative expenses1,180 1,419 3,549 4,853 Loss from operations(2,733)(3,570)(8,832)(13,382)Other segment items (f)62 57 277 295 Net loss$(2,671)$(3,513)$(8,555)$(13,087)*Completed study(a)Completed study.(b)In March 2025, the Company paused new site activations and patient enrollments due to funding constraints.(c)In September 2025, the Company paused new patient enrollment to revise the dosing regimen for patients receiving INT230-6.(d)Consulting & Other includes research and development consulting costs and travel-related costs. (e)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs. 

(f)Other segment items include interest income, interest expense, and foreign exchange gains and losses. 

13

Note 13.    Subsequent Events

ATM Sales Agreement IssuancesSubsequent to September 30, 2025, the Company issued 5,930,344 shares of common stock under the ATM Sales Agreement for net proceeds of $2.0 million. October 2025 Registered Direct OfferingOn October 30, 2025, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the investor 5,000,000 shares of common stock at a price of $0.80 per share, for aggregate gross proceeds of $4.0 million before deducting the placement agent’s fees and related offering expenses.

14

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our 2024 Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and financing needs, includes forward